A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
ConditionNeoplasms
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorJohnson & Johnson Enterprise Innovation Inc.
About this trial
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Eligibility criteria
Qualifiers
For Part 1: Individuals with a diagnosis of advanced or metastatic solid tumor exhausting all available standard of care therapy; Part 2: Individuals with histologically or cytologically confirmed metastatic or locally advanced NSCLC
Have at least 1 injectable tumor
Eastern cooperative oncology group (ECOG) performance status of grade 0 or 1
A participant who can have children must have a negative pregnancy test before the first dose of study treatment and during the study
Disqualifiers
Active disease involvement of the CNS (example, primary central nervous system tumors, metastases, leptomeningeal disease). Some exceptions are allowed
Prior history of, or active, significant herpetic infections (example, herpetic keratitis or encephalitis) or active herpetic infections that require ongoing systemic anti-viral therapy
Active infection or condition that requires treatment with systemic anti-infective agents (example, antibiotics, antifungals, or antivirals) within 7 days prior to the first dose of study treatment or chronic use of anti-infective agents
History of solid organ or hematologic stem cell transplantation
Trial design
Treatments tested in this trial
- JNJ-87704916
- Cetrelimab
- Standard of Care PD(L)-1
Treatment groups
126 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov